FDA Approved: DAPTOMYCIN — Supplemental Application (BE Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approves BE Pharmaceuticals Inc.'s supplemental application for daptomycin. This action updates the regulatory status for the drug under theANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Infective Endocarditis
• Skin and Soft Tissue Infections

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

SUPPL AP for DAPTOMYCIN (DAPTOMYCIN)